Kiniksa Pharmaceuticals Ltd KNSA:NASDAQ

RT Quote | Last NASDAQ LS, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/16/24 EDT
20.11UNCH (UNCH)
Volume
17,678
Close
20.11UNCH (UNCH)
Volume
285,885
52 week range
13.02 - 22.09
Loading...
  • Open20.08
  • Day High20.23
  • Day Low19.87
  • Prev Close20.11
  • 52 Week High22.09
  • 52 Week High Date03/04/24
  • 52 Week Low13.02
  • 52 Week Low Date05/18/23

Key Stats

  • Market Cap1.427B
  • Shares Out70.94M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta0.34
  • YTD % Change14.65

KEY STATS

  • Open20.08
  • Day High20.23
  • Day Low19.87
  • Prev Close20.11
  • 52 Week High22.09
  • 52 Week High Date03/04/24
  • 52 Week Low13.02
  • 52 Week Low Date05/18/23
  • Market Cap1.427B
  • Shares Out70.94M
  • 10 Day Average Volume0.30M
  • Dividend-
  • Dividend Yield-
  • Beta0.34
  • YTD % Change14.65

RATIOS/PROFITABILITY

  • EPS (TTM)0.09
  • P/E (TTM)236.03
  • Fwd P/E (NTM)-121.88
  • EBITDA (TTM)-28.331M
  • ROE (TTM)2.10%
  • Revenue (TTM)301.772M
  • Gross Margin (TTM)87.75%
  • Net Margin (TTM)2.87%
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date07/23/2024(est)
  • Ex Div Date-
  • Div Amount-
  • Split Date-
  • Split Factor-

Latest On Kiniksa Pharmaceuticals Ltd

Profile

MORE
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for...
Sanjiv Patel
Chairman of the Board, Chief Executive Officer
Eben Tessari
Chief Operating Officer, Senior Vice President
Mark Ragosa
Chief Financial Officer, Senior Vice President
Michael Megna
Chief Accounting Officer, Group Vice President - Finance
Address
Clarendon House, 2 Church Street
Hamilton
HM11
Bermuda

Top Peers

SYMBOLLASTCHG%CHG
MRVI
Maravai LifeSciences Holdings Inc
11.10UNCHUNCH
PTGX
Protagonist Therapeutics Inc
31.94UNCHUNCH
DVAX
Dynavax Technologies Corp
11.28UNCHUNCH
MDXG
MiMedx Group Inc
7.89UNCHUNCH
DNA
Ginkgo Bioworks
0.839UNCHUNCH